drugset / Trial / NCT02200380
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malignancies (recipients) will be enrolled.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-03
- Completion
- 2016-04-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDX-301 | Protein / enzyme biologic | — | — |
| Subject | Plerixafor | Small molecule | — | — |